Newsroom

Featured

Lotus will market Aclasta in Taiwan to further strengthen local portfolio

Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan OTC ticker: 1795) today announced that MA of the branded product AclastaR solution for infusion was successfully transferred from Novartis Taiwan to Lotus Pharmaceutical. The acquired product for osteoporosis will be marketed in Taiwan by Lotus.

Read More
MEET THE MANAGEMENT

Highly experienced management team with a proven track record of achieving high growth and profitability.

 

News alert

Enter your email to sign up for news alerts